Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCRTR1 | O43613 | 2/20 | 0.48 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.48 |
| ▸ | S1PR1 | P21453 | 4/20 | 0.48 |
| ▸ | SCN9A | Q15858 | 7/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.43 |
| ▸ | ABL1 | P00519 | 1/20 | 0.41 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.41 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.41 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL30605726 | 0.99 | HCRTR1 (0.48) | HCRTR1HCRTR2S1PR1SCN9ACNR2 | |
| SCHEMBL21065130 | 0.83 | HCRTR1 (0.45) | HCRTR1HCRTR2S1PR1SCN9ACNR2 | |
| SCHEMBL28215405 | 0.81 | DRD1 (0.40) | HCRTR1HCRTR2CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL19900060 | 0.78 | MAOB (0.49) | SCN9ACNR2TRPA1CYP3A4 | |
| SCHEMBL16482130 | 0.78 | S1PR1 (0.50) | HCRTR1HCRTR2S1PR1SCN9ACNR2 | |
| SCHEMBL29644649 | 0.76 | NPC1 (0.45) | — | |
| SCHEMBL30093453 | 0.76 | S1PR1 (0.45) | HCRTR1HCRTR2S1PR1SCN9ACNR2 | |
| SCHEMBL4042453 | 0.75 | NOTUM (0.51) | S1PR1SCN9ACNR2CYP3A4CYP2D6 | |
| SCHEMBL21065105 | 0.75 | HCRTR1 (0.65) | HCRTR1HCRTR2 | |
| SCHEMBL21065106 | 0.75 | HCRTR1 (0.65) | HCRTR1HCRTR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | claimed |
| CN-111511731-B | Olefin compounds as modulators of the farnesol X receptor | 百时美施贵宝公司 | 2023-05-23 | — | — | CN | claimed |
| CN-115504972-B | Isoxazole derivatives, preparation method thereof and application thereof as medicines | 广东药科大学 | 2024-11-12 | — | — | CN | disclosed |
| CN-111295382-B | Bridged bicyclic compounds as farnesyl ester X receptor modulators | 百时美施贵宝公司 | 2024-02-02 | — | — | CN | disclosed |
| CN-116887827-A | Compounds and methods for modulating FXR | 拓臻制药公司 | 2023-10-13 | — | — | CN | disclosed |
| EP-3704113-B1 | BRIDGED BICYCLIC COMPOUNDS AS FARNESOID X RECEPTOR MODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2023-10-11 | — | — | EP | disclosed |
| CN-115504972-A | Isoxazole derivatives, preparation method thereof and application thereof as medicines | 广东药科大学 | 2022-12-23 | — | — | CN | disclosed |
| CN-115427030-A | Farnesoid X receptor modulating compounds and methods of using the same | 因奥必治疗有限公司 | 2022-12-02 | — | — | CN | disclosed |
| CN-112638473-B | Compounds for modulating farnesoid X receptors and methods of making and using the same | 因奥必治疗有限公司 | 2022-06-07 | — | — | CN | disclosed |
| US-20220127258-A1 | AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | The National Institutes of Pharmaceutical R&D Co., Ltd. (CN) | 2022-04-28 | — | — | US | disclosed |
| EP-3972596-A1 | COMBINATIONS COMPRISING BENZODIOXOL AS GLP-1R AGONISTS FOR USE IN THE TREATMENT OF NASH/NAFLD AND RELATED DISEASES | Pfizer Inc. (US) | 2022-03-30 | — | — | EP | disclosed |
| CN-110049982-A | Heterocyclic FXR regulator | 合帕吉恩治疗公司 | 2019-07-23 | — | — | CN | disclosed |
| CN-108064223-A | FXR (NR1H4) modulating compound of hydroxyl | 吉利德科学公司 | 2018-05-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127258-A1 | AROMATIC RING OR HETEROAROMATIC RING COMPOUNDS, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF | CYP46A1, NR1H4, CYP7A1 | HCRTR1 1444/4885HCRTR2 1040/4885S1PR1 1327/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.